Full-Life Tech and SK Biopharma ink licensing deal

German radiotherapeutics company Full-Life Technologies says it has entered into a license agreement with South Korea’s SK Biopharmaceuticals, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life's FL-091 radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers.

This licensing deal worth $571.5 million includes an upfront payment, and development and commercial milestones, separate from royalties. Under the terms of the accord, SK Biopharma will in-license the NTSR1-targeting radionuclide drug conjugate (RDC) program FL-091 - as well as its back-up compounds - aimed at developing and commercializing it as an innovative anti-cancer drug. SK Biopharma also has a right of first negotiation to license other pre-selected RDC programs of Full-Life.

FL-091 is a small-molecule radioligand vector designed to deliver targeted radiation therapy to cancer cells by binding specifically to NTSR1, a receptor protein, which is selectively overexpressed in various types of solid tumors, including colorectal cancer, prostate cancer, and pancreatic cancer.